Uptal Patel is Senior Vice President and Head of Development at HI-Bio, at Biogen, focused on targeted therapies for immune-mediated diseases. Prior to HI-Bio, he led clinical strategy, translation, and development of the kidney portfolios at AstraZeneca (within early CVRM) and Gilead Sciences (within Inflammation therapeutic area). He currently also serves as Chair of the Board of Directors for the Kidney Health Initiative. He is an adjunct Professor at Duke University where he has led clinical and translational research programs to improve detection and management of kidney disease in populations. He completed training at the University of Michigan in internal medicine, pediatrics, adult nephrology, pediatric nephrology, and health services research after attending medical school at UCSF.